L3VLUP
ProSign in

PCVX · GILD in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

PCVXGILD
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • PCVX
  • GILD
010203040202120222023202420252026
Holders and value by quarter
QuarterPCVXGILD
Q3 20202 holders, $515m25 holders, $14.2bn
Q4 20201 holders, $108m27 holders, $13.4bn
Q1 20211 holders, $84m24 holders, $14.5bn
Q2 20211 holders, $93m18 holders, $14.9bn
Q3 20211 holders, $104m20 holders, $16.4bn
Q4 20212 holders, $103m20 holders, $16.8bn
Q1 20222 holders, $106m28 holders, $13.2bn
Q2 20224 holders, $107m26 holders, $13.6bn
Q3 20225 holders, $140m24 holders, $13.3bn
Q4 202212 holders, $1.2bn32 holders, $21.1bn
Q1 20238 holders, $978m27 holders, $21.8bn
Q2 20238 holders, $1.6bn24 holders, $20.7bn
Q3 20239 holders, $1.8bn24 holders, $20.0bn
Q4 20239 holders, $2.1bn22 holders, $21.5bn
Q1 20249 holders, $2.7bn30 holders, $20.3bn
Q2 202410 holders, $3.1bn28 holders, $18.5bn
Q3 202412 holders, $5.1bn29 holders, $24.2bn
Q4 202411 holders, $3.6bn28 holders, $25.9bn
Q1 20256 holders, $1.8bn33 holders, $32.0bn
Q2 20257 holders, $969m27 holders, $30.9bn
Q3 20259 holders, $940m23 holders, $29.4bn
Q4 20259 holders, $1.8bn25 holders, $34.3bn
Q1 202612 holders, $2.7bn25 holders, $38.5bn
Q2 20268 holders, $2.9bn26 holders, $34.2bn
PCVX

Vaxcyte Inc

Holders
9
Reported value
$2.7bn
Buyers
8
Sellers
1

Breadth +7 among 93 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
GILD

Gilead Sciences Inc

Holders
30
Reported value
$20.3bn
Buyers
17
Sellers
12

Breadth +5 among 93 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q1 2024

Among the 32 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only PCVX (2)

Farallon Capital Management LLC, Maverick Capital Ltd

Only GILD (23)

Acadian Asset Management LLC, AQR Capital Management LLC, Arrowstreet Capital LP, Bridgewater Associates LP, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Eisler Capital Management Ltd, Hudson Bay Capital Management LP, Invesco Ltd, Man Group PLC, Neuberger Berman Group LLC, Point72 Asset Management LP, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, Tudor Investment Corp, Two Sigma Advisers LP, Two Sigma Investments LP, Voloridge Investment Management LLC, Winton Group Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →